Medical collaboration between Cho Ray Hospital and highly reputed international counterpart to improve quality of medical treatment

  • Collaboration between Cho Ray Hospital Oncology Center and reputed international counterpart to help improve quality of medical treatment, with Bayer Vietnam honored to act as a bridge connecting this project.
  • Partnership marked by series of medical seminars and future activities to advance level of disease prevention and treatment, benefiting patients in both countries.

Ho Chi Minh City, 10 March 2022 – Cho Ray Hospital Oncology Center and Kaohsiung Chang Gung Memorial Hospital in Taiwan, medical institutions with similarly high levels of expertise, have announced the signing of a collaboration pact. The partnership aims to improve professional growth and enhance the quality of medical examinations and treatment in their respective public healthcare systems. With years of experience in the field of oncology and a wide professional network among countries in the Asia-Pacific region, Bayer is proud to announce its role as a bridge connecting these two hospitals and is planning to hold multiple activities to support the alliance. The signing ceremony took place at Cho Ray Hospital Oncology Center in Ho Chi Minh City at the end of February with the attendance of Dr. Lam Viet Trung, Vice Director of Cho Ray Hospital Oncology Center.

With a wide professional network among countries in the Asia-Pacific region, Bayer is honored to be the bridge between the two hospitals and has many activities to support this project.

Following the ceremony, the two hospitals held a webinar themed “Treatment of hepatocellular carcinoma: practice in Vietnam and Taiwan”, hosted by Dr. Le Tuan Anh, Director of Cho Ray Hospital Oncology Center, and Dr. Sheng-nan Lu, Vice Director of Chang Gung Memorial Hospital. Leading experts from the two sides shared the latest and most appropriate treatment methods, highlighting how proper treatment, given at the right time and stage, can greatly improve the outlook for patients.

This alliance sets the ground for future collaboration on scientific exchange, education and training, as well as mutual research for the benefit of patients. Acting as a conduit to organize seminars between the two parties, Bayer will support these initiatives to enhance the cross-border sharing of best medical practices to improve the treatment of various diseases.

Medical cooperation will contribute to bringing practical benefits to medical examination and treatment activities, improving treatment effectiveness and bringing mutual benefits to patients.

Dr. Tran Thi Lan Huong, Medical Director of the Pharmaceuticals Division, Bayer Vietnam, shared: "Our goal at Bayer is to provide innovative solutions that offer patients the best possible treatments that are backed up by credible scientific evidence. One of the ways we enhance our services is through partnerships with other companies and experts. Despite the complications of the COVID-19 pandemic, a signing ceremony and an online scientific conference were held to demonstrate the urgency and commitment of the two sides. We believe this collaboration with Cho Ray Hospital Oncology Center will contribute to the development of practical values for medical examination and treatment operations, thus enhancing disease treatment in the public healthcare system and benefiting society overall."

As the world faces global health challenges, it is more important than ever to collaborate and share best treatments and harness resources for innovation.

Dr. Le Tuan Anh shared: “We appreciate Bayer’s support of the collaboration between Cho Ray Hospital Oncology Center and Kaohsiung Chang Gung Memorial Hospital. Through our joint efforts, we want to expand our field of competence, thus providing patients with optimum medical interventions.”

This is not the first time Bayer has helped build diverse global partnerships across various industries. Through this partnership, Bayer hopes to advance disease treatment in Vietnam while expanding the technological horizons of medical care. Simultaneously, Bayer is dedicated to supporting hospitals and elevating public healthcare. With the world beset by challenges that recognize no borders, collaboration, sharing best treatment practices and pooling grey matter for innovation is needed more than ever.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. 

For more information, go to

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.